New Findings from Merck & Company in the Area of Dyslipidemias Described (Cardiometabolic outcomes among schizophrenia patients using antipsychotics: the impact of high weight gain risk vs low weight gain risk treatment)

Source :: Mental Health Weekly Digest. March 7, 2022, 94
Publication Year :: 2022
Abstract: 2022 MAR 7 (NewsRx) -- By a News Reporter-Staff News Editor at Mental Health Weekly Digest -- A new study on dyslipidemias is now available. According to news reporting out [...]

Subjects :: Merck & Company Inc. -- Reports
International Business Machines Corp. -- Reports
Merck Sharp & Dohme Corp. -- Reports
Mental health -- Reports
Schizophrenia -- Patient outcomes
Medicaid -- Reports
Antipsychotic drugs -- Reports
Computer industry -- Reports
Pharmaceutical industry -- Reports
Microcomputer industry
Computer industry
Health
Psychology and mental health

Tools